Passa al contenuto
Merck
Tutte le immagini(1)

Key Documents

View All Documentation

B2635

Supelco

Busulfan

analytical standard, for drug analysis

Sinonimo/i:

1,4-Butanediol dimethanesulfonate

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula condensata:
CH3SO2O(CH2)4OSO2CH3
Numero CAS:
55-98-1
Peso molecolare:
246.30
Beilstein:
1791786
Numero CE:
200-250-2
Numero MDL:
MFCD00007562
Codice UNSPSC:
41116107
ID PubChem:
329773205
NACRES:
NA.24

Grado

analytical standard, for drug analysis

Livello qualitativo

100

tecniche

HPLC: suitable
gas chromatography (GC): suitable

Punto di fusione

114-117 °C (lit.)

applicazioni

forensics and toxicology
veterinary

Formato

neat

Stringa SMILE

CS(=O)(=O)OCCCCOS(C)(=O)=O

InChI

1S/C6H14O6S2/c1-13(7,8)11-5-3-4-6-12-14(2,9)10/h3-6H2,1-2H3
COVZYZSDYWQREU-UHFFFAOYSA-N

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Categorie correlate

Descrizione generale

Busulfan is a bifunctional alkylating agent, which may find application in the treatment of chronic granulocytic leukemia.

Applicazioni

Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.

Pittogrammi

Skull and crossbonesHealth hazard
GHS06,GHS08

Avvertenze

Danger

Indicazioni di pericolo

H301,H340,H350,H360FD

Classi di pericolo

Acute Tox. 3 Oral - Carc. 1A - Muta. 1B - Repr. 1B

Codice della classe di stoccaggio

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number
BCCG5556
BCCF4469
BCCC6140
BCBZ9160
BCBW8235

Non trovi la versione di tuo interesse?

Se hai bisogno di una versione specifica, puoi cercare il certificato tramite il numero di lotto.

Cerca un COA

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 5

1 of 5

vibrant-m

Y0001457

Melphalan for system suitability

Cyclophosphamide British Pharmacopoeia (BP) Reference Standard

BP1094

Cyclophosphamide

Ifosfamide ≥98%

Sigma-Aldrich

I4909

Ifosfamide

Cyclophosphamide Monohydrate A widely used anti-neoplastic agent that also displays immunosuppressant properties.

Sigma-Aldrich

239785

Cyclophosphamide Monohydrate

Poli(etilenglicole) average mol wt 400

Sigma-Aldrich

P3265

Poli(etilenglicole)

Blood and Marrow Stem Cell Transplantation: Principles, Practice, and Nursing Insights (1997)
Arnon Nagler et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(28), 3549-3556 (2013-08-28)
Cyclophosphamide (Cy) combined with total-body irradiation (TBI) or with busulfan (Bu) are currently the most common myeloablative regimens used in allogeneic stem-cell transplantation (alloSCT) in adults with acute myelogenous leukemia (AML). Intravenous (IV) Bu has more predictable bioavailability and a
Manabu Ozawa et al.
Biology of reproduction, 94(4), 92-92 (2016-03-18)
The F-box and leucine-rich repeat protein 10 (Fbxl10) gene encodes a protein that catalyzes demethylation of H3K4 and H3K36. In this study, we show the important roles of FBXL10 as a histone demethylase in sustainable sperm production using mice in
Edward A Copelan et al.
Blood, 122(24), 3863-3870 (2013-09-26)
Cyclophosphamide combined with total body irradiation (Cy/TBI) or busulfan (BuCy) are the most widely used myeloablative conditioning regimens for allotransplants. Recent data regarding their comparative effectiveness are lacking. We analyzed data from the Center for International Blood and Marrow Transplant
Christopher Bredeson et al.
Blood, 122(24), 3871-3878 (2013-10-02)
We conducted a prospective cohort study testing the noninferiority of survival of ablative intravenous busulfan (IV-BU) vs ablative total body irradiation (TBI)-based regimens in myeloid malignancies. A total of 1483 patients undergoing transplantation for myeloid malignancies (IV-BU, N = 1025;
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.